02:43 , Jun 1, 2019 |  BioCentury  |  Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
23:41 , Apr 26, 2018 |  BC Innovations  |  Product R&D

Brake for gas

Elpiscience Biopharmaceuticals Co. Ltd. has emerged from stealth mode with an unconventional bispecific that simultaneously removes the brakes and steps on the gas for antitumor immunity, but only inside tumors. The goal is to upstage...
23:39 , Dec 4, 2017 |  BC Extra  |  Company News

Management Tracks: Athenex, Biogen

Cancer company Athenex Inc. (NASDAQ:ATNX) said CFO Nick Riehle will retire, effective Dec. 31. VP of financial reporting Li Shen will serve as acting chief accounting officer as the company seeks a replacement. Biogen Inc....
02:16 , Apr 22, 2017 |  BioCentury  |  Finance

Sweden heating up

Following a nearly 15-year deep freeze, Stockholm has become one of the hottest European markets for biotech IPOs. The recent boom reflects a ripening of several years of investment in the early stage life sciences...
07:00 , Jul 14, 2016 |  BC Innovations  |  Product R&D

Agonistic families

TNF superfamily receptors and their ligands have long been recognized as clinically relevant therapeutic targets for cancer, and dozens of companies are using different therapeutic modalities to target the proteins. Apogenix AG is one of...
07:00 , Aug 17, 2015 |  BC Week In Review  |  Company News

Alligator Bioscience, J&J deal

Alligator granted Johnson & Johnson’s Janssen Biotech Inc. unit exclusive, worldwide rights to develop and commercialize ADC-1013 . Alligator expects to complete a Phase I trial of the antibody-based CD40 receptor activator immunotherapy in solid...
07:00 , Aug 17, 2015 |  BC Week In Review  |  Financial News

Alligator Bioscience completes venture financing

Alligator Bioscience AB , Lund, Sweden   Business: Antibodies, Cancer   Date completed: 2015-08-12   Type: Venture financing   Raised: Not disclosed   Investor: Johnson & Johnson Development Corp.   Note: The amount raised is...
01:46 , Aug 13, 2015 |  BC Extra  |  Company News

Janssen snaps up Alligator's immunotherapy candidate

Alligator Bioscience AB (Lund, Sweden) granted the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ) exclusive, worldwide rights to cancer immunotherapy candidate ADC-1013 . Under a separate agreement, J&J's venture arm Johnson & Johnson...
07:00 , Jun 9, 2014 |  BC Week In Review  |  Company News

Alligator Bioscience, BioInvent deal

BioInvent sold back all rights to preclinical cancer compound ADC-1013 to former partner Alligator for an undisclosed sum. BioInvent has successfully manufactured the antibody-based CD40 receptor activator immunotherapy and will fulfill the remaining activities required...
08:00 , Jan 6, 2011 |  BC Innovations  |  Strategy

LU Bio: Swedish hybrid

Lund University Bioscience AB is not a typical investment company or VC. As a kind of hybrid between a company, an incubator and a VC, LU Bio seeks out technology with commercial potential from academic...